An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)

Lance A Wollenberg,1 Donald T Corson,2,3 Courtney A Nugent,1 Farran L Peterson,1 Ann M Ptaszynski,1 Alisha Arrigo,2,3 Coralee G Mannila,2,3 Kevin S Litwiler,1 Stacie J Bell1,4 1Array BioPharma, Boulder, 2Array BioPharma, Longmont, CO, 3Avista Pharma Solutions, Longmont, CO, 4Mallinckrodt Pharmaceuti...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wollenberg LA, Corson DT, Nugent CA, Peterson FL, Ptaszynski AM, Arrigo A, Mannila CG, Litwiler KS, Bell SJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/11297fe8bc8b44588adb1e51fd578016
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:11297fe8bc8b44588adb1e51fd578016
record_format	dspace
spelling	oai:doaj.org-article:11297fe8bc8b44588adb1e51fd5780162021-12-02T01:00:44ZAn exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)1179-1438https://doaj.org/article/11297fe8bc8b44588adb1e51fd5780162015-09-01T00:00:00Zhttps://www.dovepress.com/an-exploratory-randomized-parallel-group-open-label-relative-bioavaila-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Lance A Wollenberg,1 Donald T Corson,2,3 Courtney A Nugent,1 Farran L Peterson,1 Ann M Ptaszynski,1 Alisha Arrigo,2,3 Coralee G Mannila,2,3 Kevin S Litwiler,1 Stacie J Bell1,4 1Array BioPharma, Boulder, 2Array BioPharma, Longmont, CO, 3Avista Pharma Solutions, Longmont, CO, 4Mallinckrodt Pharmaceuticals, Ellicott City, MD, USA Background: Pexmetinib (ARRY-614) is a dual inhibitor of p38 mitogen-activated protein kinase and Tie2 signaling pathways implicated in the pathogenesis of myelodysplastic syndromes. Previous clinical experience in a Phase I dose-escalation study of myelodysplastic syndrome patients using pexmetinib administered as neat powder-in-capsule (PIC) exhibited high variability in pharmacokinetics and excessive pill burden, prompting an effort to improve the formulation of pexmetinib. Methods: A relative bioavailability assessment encompassed three parallel treatment cohorts of unique subjects comparing the two new formulations (12 subjects per cohort), a liquid oral suspension (LOS) and liquid-filled capsule (LFC) and the current clinical PIC formulation (six subjects) in a fasted state. The food-effect assessment was conducted as a crossover of the LOS and LFC formulations administered under fed and fasted conditions. Subjects were divided into two groups of equal size to evaluate potential period effects on the food-effect assessment. Results: The geometric mean values of the total plasma exposures based upon area-under-the-curve to the last quantifiable sample (AUClast) of pexmetinib were approximately four- and twofold higher after administration of the LFC and LOS formulations, respectively, than after the PIC formulation, when the formulations were administered in the fasted state. When the LFC formulation was administered in the fed state, pexmetinib AUClast decreased by <5% compared with the fasted state. After administration of the LOS formulation in the fed state, pexmetinib AUClast was 34% greater than observed in the fasted state. Conclusion: These results suggest that the LFC formulation of pexmetinib may achieve greater exposures with lower doses due to the greater bioavailability compared to the PIC, and remain unaffected by coadministration with food. Keywords: pexmetinib, myelodysplastic syndromes, liquid-filled capsule, bioavailability, food-effect, formulation Wollenberg LACorson DTNugent CAPeterson FLPtaszynski AMArrigo AMannila CGLitwiler KSBell SJDove Medical PressarticleTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol 2015, Iss default, Pp 87-95 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Therapeutics. Pharmacology RM1-950
spellingShingle	Therapeutics. Pharmacology RM1-950 Wollenberg LA Corson DT Nugent CA Peterson FL Ptaszynski AM Arrigo A Mannila CG Litwiler KS Bell SJ An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)
description	Lance A Wollenberg,1 Donald T Corson,2,3 Courtney A Nugent,1 Farran L Peterson,1 Ann M Ptaszynski,1 Alisha Arrigo,2,3 Coralee G Mannila,2,3 Kevin S Litwiler,1 Stacie J Bell1,4 1Array BioPharma, Boulder, 2Array BioPharma, Longmont, CO, 3Avista Pharma Solutions, Longmont, CO, 4Mallinckrodt Pharmaceuticals, Ellicott City, MD, USA Background: Pexmetinib (ARRY-614) is a dual inhibitor of p38 mitogen-activated protein kinase and Tie2 signaling pathways implicated in the pathogenesis of myelodysplastic syndromes. Previous clinical experience in a Phase I dose-escalation study of myelodysplastic syndrome patients using pexmetinib administered as neat powder-in-capsule (PIC) exhibited high variability in pharmacokinetics and excessive pill burden, prompting an effort to improve the formulation of pexmetinib. Methods: A relative bioavailability assessment encompassed three parallel treatment cohorts of unique subjects comparing the two new formulations (12 subjects per cohort), a liquid oral suspension (LOS) and liquid-filled capsule (LFC) and the current clinical PIC formulation (six subjects) in a fasted state. The food-effect assessment was conducted as a crossover of the LOS and LFC formulations administered under fed and fasted conditions. Subjects were divided into two groups of equal size to evaluate potential period effects on the food-effect assessment. Results: The geometric mean values of the total plasma exposures based upon area-under-the-curve to the last quantifiable sample (AUClast) of pexmetinib were approximately four- and twofold higher after administration of the LFC and LOS formulations, respectively, than after the PIC formulation, when the formulations were administered in the fasted state. When the LFC formulation was administered in the fed state, pexmetinib AUClast decreased by <5% compared with the fasted state. After administration of the LOS formulation in the fed state, pexmetinib AUClast was 34% greater than observed in the fasted state. Conclusion: These results suggest that the LFC formulation of pexmetinib may achieve greater exposures with lower doses due to the greater bioavailability compared to the PIC, and remain unaffected by coadministration with food. Keywords: pexmetinib, myelodysplastic syndromes, liquid-filled capsule, bioavailability, food-effect, formulation
format	article
author	Wollenberg LA Corson DT Nugent CA Peterson FL Ptaszynski AM Arrigo A Mannila CG Litwiler KS Bell SJ
author_facet	Wollenberg LA Corson DT Nugent CA Peterson FL Ptaszynski AM Arrigo A Mannila CG Litwiler KS Bell SJ
author_sort	Wollenberg LA
title	An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)
title_short	An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)
title_full	An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)
title_fullStr	An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)
title_full_unstemmed	An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)
title_sort	exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (arry-614)
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/11297fe8bc8b44588adb1e51fd578016
work_keys_str_mv	AT wollenbergla anexploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT corsondt anexploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT nugentca anexploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT petersonfl anexploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT ptaszynskiam anexploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT arrigoa anexploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT mannilacg anexploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT litwilerks anexploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT bellsj anexploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT wollenbergla exploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT corsondt exploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT nugentca exploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT petersonfl exploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT ptaszynskiam exploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT arrigoa exploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT mannilacg exploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT litwilerks exploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614 AT bellsj exploratoryrandomizedparallelgroupopenlabelrelativebioavailabilitystudywithanadditionaltwoperiodcrossoverfoodeffectstudyexploringthepharmacokineticsoftwonovelformulationsofpexmetinibarry614
_version_	1718403360613203968

An exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (ARRY-614)

Ejemplares similares